161 related articles for article (PubMed ID: 25056817)
1. Fast-growing in-transit melanoma metastasis after intratumoral interleukin-2.
Moreno-Ramírez D; Alés-Martínez M; Ferrándiz L
Cancer Immunol Immunother; 2014 Nov; 63(11):1229-30. PubMed ID: 25056817
[No Abstract] [Full Text] [Related]
2. Limited efficacy of intratumoral IL-2 applied to large melanoma metastases.
Weide B; Eigentler TK; Elia G; Neri D; Garbe C
Cancer Immunol Immunother; 2014 Nov; 63(11):1231-2. PubMed ID: 25056818
[No Abstract] [Full Text] [Related]
3. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.
Weide B; Eigentler TK; Pflugfelder A; Leiter U; Meier F; Bauer J; Schmidt D; Radny P; Pföhler C; Garbe C
Cancer Immunol Immunother; 2011 Apr; 60(4):487-93. PubMed ID: 21174093
[TBL] [Abstract][Full Text] [Related]
4. Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease.
Hassan S; Petrella TM; Zhang T; Kamel-Reid S; Nordio F; Baccarelli A; Sade S; Naert K; Habeeb AA; Ghazarian D; Wright FC
Ann Surg Oncol; 2015; 22(6):1950-8. PubMed ID: 25366584
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
Kirkwood JM; Tarhini AA
J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
[No Abstract] [Full Text] [Related]
6. [Prognostic significance of DNA ploidy in disseminated malignant skin melanoma and the effectiveness of interleukin-2 (IL-2) treatment].
Novik AV; Novik BI; Moiseenko VM
Vopr Onkol; 2007; 53(2):164-9. PubMed ID: 17663169
[TBL] [Abstract][Full Text] [Related]
7. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
Schwartzentruber DJ; Lawson DH; Richards JM; Conry RM; Miller DM; Treisman J; Gailani F; Riley L; Conlon K; Pockaj B; Kendra KL; White RL; Gonzalez R; Kuzel TM; Curti B; Leming PD; Whitman ED; Balkissoon J; Reintgen DS; Kaufman H; Marincola FM; Merino MJ; Rosenberg SA; Choyke P; Vena D; Hwu P
N Engl J Med; 2011 Jun; 364(22):2119-27. PubMed ID: 21631324
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy and chemoimmunotherapy for metastatic malignant melanoma: review and recent advances.
Khayat D; Coeffic D
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():238-47. PubMed ID: 10895160
[No Abstract] [Full Text] [Related]
9. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
Dutcher JP
Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
[No Abstract] [Full Text] [Related]
10. Chemotherapy, cytokines, and biochemotherapy for melanoma.
Eton O
Cancer Chemother Biol Response Modif; 2005; 22():739-48. PubMed ID: 16110637
[No Abstract] [Full Text] [Related]
11. What can we learn from phase II adjuvant trials in melanoma?
Keilholz U; Suciu S; Eggermont AM
Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
[No Abstract] [Full Text] [Related]
12. Inhibition of the growth of murine malignant melanoma by polyinosinic-polycytidylic acid.
Bart RS; Kopf AW; Silagi S
J Invest Dermatol; 1971 Jan; 56(1):33-8. PubMed ID: 5556497
[No Abstract] [Full Text] [Related]
13. Node positive melanoma--a positive note?
Kelly J; Kerin MJ
Surgeon; 2012 Apr; 10(2):63-4. PubMed ID: 22385525
[No Abstract] [Full Text] [Related]
14. Treating metastatic melanoma: further considerations.
Legha SS
Oncology (Williston Park); 2009 May; 23(6):500, 508. PubMed ID: 19544691
[No Abstract] [Full Text] [Related]
15. [Zelboraf. Longer term survival for advanced stage melanoma].
Sabourin G
Perspect Infirm; 2012; 9(5):64-5. PubMed ID: 22978138
[No Abstract] [Full Text] [Related]
16. Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review.
Byers BA; Temple-Oberle CF; Hurdle V; McKinnon JG
J Surg Oncol; 2014 Nov; 110(6):770-5. PubMed ID: 24996052
[TBL] [Abstract][Full Text] [Related]
17. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.
Ellebaek E; Engell-Noerregaard L; Iversen TZ; Froesig TM; Munir S; Hadrup SR; Andersen MH; Svane IM
Cancer Immunol Immunother; 2012 Oct; 61(10):1791-804. PubMed ID: 22426890
[TBL] [Abstract][Full Text] [Related]
18. Malignant melanoma.
Moore GE; Gerner RE
Surg Gynecol Obstet; 1971 Mar; 132(3):427-36. PubMed ID: 5546295
[No Abstract] [Full Text] [Related]
19. [Therapy of malignant melanoma at the stage of distant metastasis].
Garbe C; Eigentler TK
Hautarzt; 2004 Feb; 55(2):195-213. PubMed ID: 15043023
[TBL] [Abstract][Full Text] [Related]
20. [In vitro drug sensitivity profiling in melanoma].
Ugurel S
J Dtsch Dermatol Ges; 2008 Jul; 6(7):611. PubMed ID: 18611186
[No Abstract] [Full Text] [Related]
[Next] [New Search]
